KR102763158B1 - 최적화된 항tl1a 항체 - Google Patents

최적화된 항tl1a 항체 Download PDF

Info

Publication number
KR102763158B1
KR102763158B1 KR1020207034024A KR20207034024A KR102763158B1 KR 102763158 B1 KR102763158 B1 KR 102763158B1 KR 1020207034024 A KR1020207034024 A KR 1020207034024A KR 20207034024 A KR20207034024 A KR 20207034024A KR 102763158 B1 KR102763158 B1 KR 102763158B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
antigen
binding fragment
tl1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034024A
Other languages
English (en)
Korean (ko)
Other versions
KR102763158B9 (ko
KR20210005169A (ko
Inventor
제프리 디 왓킨스
신디 티 디커슨
제이 몬티 왓킨스
패트리샤 맥닐리
Original Assignee
프로메테우스 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 바이오사이언시즈, 인크. filed Critical 프로메테우스 바이오사이언시즈, 인크.
Priority to KR1020257003190A priority Critical patent/KR20250024101A/ko
Publication of KR20210005169A publication Critical patent/KR20210005169A/ko
Application granted granted Critical
Publication of KR102763158B1 publication Critical patent/KR102763158B1/ko
Publication of KR102763158B9 publication Critical patent/KR102763158B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207034024A 2018-04-25 2019-04-24 최적화된 항tl1a 항체 Active KR102763158B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257003190A KR20250024101A (ko) 2018-04-25 2019-04-24 최적화된 항tl1a 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862662605P 2018-04-25 2018-04-25
US62/662,605 2018-04-25
US201862756494P 2018-11-06 2018-11-06
US62/756,494 2018-11-06
PCT/US2019/028987 WO2019209995A2 (en) 2018-04-25 2019-04-24 Optimized anti-tl1a antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257003190A Division KR20250024101A (ko) 2018-04-25 2019-04-24 최적화된 항tl1a 항체

Publications (3)

Publication Number Publication Date
KR20210005169A KR20210005169A (ko) 2021-01-13
KR102763158B1 true KR102763158B1 (ko) 2025-02-04
KR102763158B9 KR102763158B9 (ko) 2025-06-19

Family

ID=68295788

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207034024A Active KR102763158B1 (ko) 2018-04-25 2019-04-24 최적화된 항tl1a 항체
KR1020257003190A Pending KR20250024101A (ko) 2018-04-25 2019-04-24 최적화된 항tl1a 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257003190A Pending KR20250024101A (ko) 2018-04-25 2019-04-24 최적화된 항tl1a 항체

Country Status (10)

Country Link
US (5) US20210070871A1 (enExample)
EP (1) EP3784699A4 (enExample)
JP (2) JP7332627B2 (enExample)
KR (2) KR102763158B1 (enExample)
CN (2) CN112585165B8 (enExample)
AU (2) AU2019261426A1 (enExample)
CA (1) CA3098374A1 (enExample)
MA (1) MA52366A (enExample)
TW (2) TWI842707B (enExample)
WO (1) WO2019209995A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＴＬ１ａに対する抗体およびその使用
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20190082815A (ko) * 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
WO2020112890A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
TWI871367B (zh) * 2019-10-24 2025-02-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
MX2022004942A (es) * 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
BR112022025667A2 (pt) * 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
JP2023551602A (ja) * 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
TW202246322A (zh) * 2021-02-18 2022-12-01 美商普羅米修斯生物科學股份有限公司 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
WO2024037621A1 (en) * 2022-08-19 2024-02-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ptk7-binding protein and use thereof
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒
WO2025038473A1 (en) * 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN120530139A (zh) * 2023-12-29 2025-08-22 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用
WO2025158389A1 (en) 2024-01-24 2025-07-31 Shattuck Labs, Inc. Antibodies that bind tnfrsf25
JP2025115976A (ja) 2024-01-26 2025-08-07 フューチャージェン・バイオファーマシューティカル（ベイジン）カンパニー・リミテッド Ｔｌ１ａに特異的に結合できる抗体及びその使用
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064854A2 (en) * 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
ES2285701T3 (es) 1994-11-07 2007-11-16 Human Genome Sciences, Inc. Factor-gamma de necrosis tumoral.
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU5124500A (en) 1999-04-30 2000-11-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
WO2002004643A1 (en) 2000-07-07 2002-01-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
CA2391711A1 (en) 2001-06-26 2002-12-26 University Of Guelph Non-radioactive assay of lipopolysaccharide kinases
EP2295468B1 (en) * 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
WO2004050836A2 (en) 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20050101889A1 (en) 2003-11-06 2005-05-12 Freeman Gary A. Using chest velocity to process physiological signals to remove chest compression artifacts
CA2573293A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
KR100596277B1 (ko) 2004-08-20 2006-07-03 동부일렉트로닉스 주식회사 반도체 소자 및 그의 절연막 형성 방법
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CN103145840A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1919954B1 (en) 2005-08-30 2016-10-19 University of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US9068003B2 (en) 2007-01-10 2015-06-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US9896511B2 (en) * 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
WO2008106579A2 (en) 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
CN101469270B (zh) 2007-12-27 2012-08-22 牛斌 工业连续化塑料裂解器
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
CA2805054A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
CA2810465C (en) 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
MY171135A (en) 2011-06-03 2019-09-27 Xoma Technology Ltd Antibodies specific for tgf-beta
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＴＬ１ａに対する抗体およびその使用
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CA2876099A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
WO2014051109A1 (ja) * 2012-09-28 2014-04-03 協和発酵キリン株式会社 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
JP2016503818A (ja) 2013-01-02 2016-02-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｌ１ａと結合する抗体およびその使用
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
JP6824735B2 (ja) * 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
CA2929784C (en) 2013-11-13 2019-11-26 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
ES2811274T3 (es) * 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
MX2016014346A (es) 2014-05-02 2017-04-27 Teva Pharma Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
LT3224275T (lt) 2014-11-14 2020-05-25 F. Hoffmann-La Roche Ag Antigeną surišančios molekulės, apimančios tnf šeimos ligando trimerą
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
WO2016162356A1 (en) * 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-pd-l1 immunotoxin for use in therapy
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
IL262244B2 (en) 2016-04-29 2024-01-01 Pfizer Antibodies against beta interferon and their use
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
SG11202003212PA (en) 2017-10-10 2020-05-28 Sanofi Sa Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301204B2 (en) 2018-07-12 2025-10-23 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
PE20211279A1 (es) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fc
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
TWI871367B (zh) 2019-10-24 2025-02-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064854A2 (en) * 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a

Also Published As

Publication number Publication date
US10689439B2 (en) 2020-06-23
JP2023166402A (ja) 2023-11-21
CN112585165B8 (zh) 2025-02-14
WO2019209995A3 (en) 2019-12-12
AU2025242193A1 (en) 2025-11-27
EP3784699A4 (en) 2022-04-13
TWI870300B (zh) 2025-01-11
US20200157203A1 (en) 2020-05-21
US20210070871A1 (en) 2021-03-11
TWI842707B (zh) 2024-05-21
CN112585165A (zh) 2021-03-30
MA52366A (fr) 2021-03-03
US20230192835A1 (en) 2023-06-22
KR20250024101A (ko) 2025-02-18
TW201945396A (zh) 2019-12-01
WO2019209995A2 (en) 2019-10-31
AU2019261426A1 (en) 2020-12-03
TW202434648A (zh) 2024-09-01
US20240368263A1 (en) 2024-11-07
KR102763158B9 (ko) 2025-06-19
CA3098374A1 (en) 2019-10-31
JP2021521843A (ja) 2021-08-30
CN119735681A (zh) 2025-04-01
EP3784699A2 (en) 2021-03-03
US20200255510A1 (en) 2020-08-13
US11440954B2 (en) 2022-09-13
JP7332627B2 (ja) 2023-08-23
KR20210005169A (ko) 2021-01-13
CN112585165B (zh) 2025-01-21

Similar Documents

Publication Publication Date Title
KR102763158B1 (ko) 최적화된 항tl1a 항체
US11680100B2 (en) B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
TWI832808B (zh) 中和抗tl1a之單株抗體
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
WO2017084495A1 (zh) Pd-l1抗体、其抗原结合片段及其医药用途
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN116323666A (zh) Fgfr3抗体和使用方法
US20220010003A1 (en) Anti-periostin antibodies and uses thereof
CN114761042A (zh) Il-38特异性抗体
HK40042163A (en) Optimized anti-tl1a antibodies
WO2025201517A1 (zh) 抗cd93抗体、其抗原结合片段及其应用
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220422

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240122

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241028

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250131

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250131

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PG1701 Publication of correction